LivingGLP1
Study S000760

The Effects of Tirzepatide on Coronary Plaque Lipid Content and Myocardial Microvascular Function in Overweight and Obese People With Coronary Disease - The IDEAL-COR Study

ClinicalTrials.gov record

Registration

Registration
NCT06606821
Acronym
IDEAL-COR
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE4
Masking
TRIPLE
Status
RECRUITING
Enrollment
124
Start
2024-10-01
Primary completion
2027-03-20
Lead sponsor
Tina Vilsbøll
Conditions
Coronary Artery Disease; Coronary Microvascular Dysfunction; Overweight or Obesity; Stable Angina Pectoris; Chronic Coronary Artery Disease; Atherosclerosis Cardiovascular Disease
Interventions
DRUG:Tirzepatide; DRUG:Placebo
Results posted
FALSE
Individual participant data sharing
YES
Secondary identifiers
CTIS:2023-505270-15-00; NIH:2023

Registered primary outcomes

  • Lipid core burden index [Between-group difference in change from baseline to week 52 in participants treated with tirzepatide vs placebo:]

Linked records (10)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0010987Tirzepatide Once Weekly for the Treatment of Obesity.
Jastreboff AM, The New England journal of medicine
2022Randomized trialPMID 35658024DOIregistry reference BACKGROUND:35658024
R0013656Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
Frías JP, The New England journal of medicine
2021Randomized trialPMID 34170647DOIregistry reference BACKGROUND:34170647
R0012365Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Kristensen SL, The lancet. Diabetes & endocrinology
2019Systematic reviewPMID 31422062DOIregistry reference BACKGROUND:31422062
R0013480Heterogeneity and Similarities in GLP-1 Receptor Agonist Cardiovascular Outcomes Trials.
Caruso I, Trends in endocrinology and metabolism: TEM
2019Other trialPMID 31401015DOIregistry reference BACKGROUND:31401015
R0018537Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Gerstein HC, Lancet (London, England)
2019Randomized trialPMID 31189511DOIregistry reference BACKGROUND:31189511
R0012223Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.
Hernandez AF, Lancet (London, England)
2018Randomized trialPMID 30291013DOIregistry reference BACKGROUND:30291013
R0014066LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
Coskun T, Molecular metabolism
2018Randomized trialPMID 30473097DOIregistry reference BACKGROUND:30473097
R0016215Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Frias JP, Lancet (London, England)
2018Randomized trialPMID 30293770DOIregistry reference BACKGROUND:30293770
R0022060Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Marso SP, The New England journal of medicine
2016Randomized trialPMID 27295427DOIregistry reference BACKGROUND:27295427
R0022278Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Marso SP, The New England journal of medicine
2016Randomized trialPMID 27633186DOIregistry reference BACKGROUND:27633186